Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:
BTIG Biotechnology Conference 2022
2022 Wedbush PacGrow Healthcare Virtual Conference
A live webcast and replay of the fireside chat at 2022 Wedbush PacGrow Healthcare Conference will also be available in the Investors section of Replimune’s website at www.replimune.com.